• Iodine
• Obesity
• Risk factors
• Thyroid cancer
• Umbrella review

• Humans
• Thyroid Neoplasms/epidemiology
• Thyroid Neoplasms/etiology
• Risk Factors
• Female

• No. ZYGD 18017 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University

• Case–control studies
• Contraceptives, Oral
• Iran
• Risk factors
• Thyroid Cancer, Papillary

• Humans
• Female
• Case-Control Studies
• Iran/epidemiology
• Thyroid Neoplasms/epidemiology
• Thyroid Neoplasms/etiology
• Thyroid Neoplasms/pathology
• Risk Factors
• Thyroid Cancer, Papillary/epidemiology
• Thyroid Cancer, Papillary/etiology
• Thyroid Cancer, Papillary/pathology
• Middle Aged
• Adult
• Prognosis
• Follow-Up Studies

• cancer risk factors
• contraceptive use
• epidemiology
• female health
• hormonal factors
• public health
• reproductive factors
• saudi arabia
• tertiary hospital
• thyroid disorders

• diane-35
• oral contraceptives
• thyroid cancer

• Humans
• Female
• Cyproterone Acetate/adverse effects
• Contraceptives, Oral/adverse effects
• Retrospective Studies
• Thyroid Neoplasms/chemically induced
• Thyroid Neoplasms/epidemiology
• Taiwan/epidemiology
• Incidence

Over the past decades, the incidence of thyroid cancer (TC) rapidly increased all over the world, with the papillary thyroid cancer (PTC) accounting for the vast majority of TC cases. It is crucial to investigate novel diagnostic and therapeutic targets for PTC and explore more detailed molecular mechanisms in the carcinogenesis and progression of PTC. Based on the TCGA and GEO databases, FAM111B is downregulated in PTC tissues and predicts better prognosis in PTC patients. FAM111B suppresses the growth, migration, invasion and glycolysis of PTC both in vitro and in vivo. Furthermore, estrogen inhibits FAM111B expression by DNMT3B methylation via enhancing the recruitment of DNMT3B to FAM111B promoter. DNMT3B-mediated FAM111B methylation accelerates the growth, migration, invasion and glycolysis of PTC cells. In clinical TC patient specimens, the expression of FAM111B is inversely correlated with the expressions of DNMT3B and the glycolytic gene PGK1. Besides, the expression of FAM111B is inversely correlated while DNMT3B is positively correlated with glucose uptake in PTC patients. Our work established E2/DNMT3B/FAM111B as a crucial axis in regulating the growth and progression of PTC. Suppression of DNMT3B or promotion of FAM111B will be potential promising strategies in the estrogen induced PTC.

• DNMT3B
• Estrogen
• FAM111B
• Glycolysis
• Papillary thyroid cancer

• breast cancer
• estrogen
• obesity
• thyroid cancer
• thyroid hormones

• Antineoplastic Agents, Hormonal/therapeutic use
• Breast Neoplasms/metabolism
• Estrogens/therapeutic use
• Female
• Gonadal Steroid Hormones
• Humans
• Thyroid Hormones/metabolism
• Thyroid Neoplasms/drug therapy

• R01 CA214511 NCI NIH HHS
• National Institutes of Health
• Children’s Hospital of Philadelphia Intramural Frontier Grant

• Adult
• Cohort Studies
• Contraceptive Agents, Hormonal/adverse effects
• Drug-Related Side Effects and Adverse Reactions/epidemiology
• Drug-Related Side Effects and Adverse Reactions/etiology
• Female
• Humans
• Long Term Adverse Effects/chemically induced
• Long Term Adverse Effects/epidemiology
• Meta-Analysis as Topic
• Pregnancy
• Randomized Controlled Trials as Topic
• Systematic Reviews as Topic
• Women's Health/statistics & numerical data

In a recent systematic review and meta-analysis of observational studies, the author found potential errors in the selection and extraction processes. The recalculated summary relative risks and the results of a dose-response meta-analysis showed that oral contraceptive use may not be associated with the risk of pancreatic cancer in women.

• Pancreas neoplasms
• Oral contraceptives
• Risk factor
• Meta-analysis
• Risk assessment
• Systematic review

• Contraceptives, Oral/adverse effects
• Female
• Humans
• Pancreatic Neoplasms/chemically induced
• Pancreatic Neoplasms/epidemiology
• Prospective Studies
• Risk
• Risk Factors

• cross-sectional study
• hysterectomy
• number of children
• oophorectomy
• oral contraceptives
• thyroid cancer

• Aged
• Child
• Cross-Sectional Studies
• Female
• Humans
• Hysterectomy
• Ovariectomy
• Risk Factors
• Thyroid Neoplasms/epidemiology

• Breast cancer
• Cervical cancer
• Endometrial cancer
• Endometriosis
• Melanoma
• Thyroid cancer

• Breast Neoplasms/etiology
• Endometriosis/complications
• Female
• Humans
• Melanoma/etiology
• Risk Factors

• Breast cancer
• Cancer
• Cervical cancer
• Colorectal cancer
• Contraception
• Contraceptive
• Endometrial cancer
• Estrogen
• Ovarian cancer
• Progestogen

• Breast cancer
• Cancer du sein
• Cancer recurrence
• Cancer risk
• Clinical guidelines
• Contraception
• Contraception after cancer
• Contraception après cancer
• Recommandations
• Risque de cancer
• Récidive de cancer

In vivo and in vitro studies have indicated the link of cholesterol consumption and endometrial cancer risk, however, previous observational studies have yielded inconsistent results. Additionally, a previous meta-analysis published in 2007 found limited evidence of aforementioned association. Therefore, we performed the dose-response meta-analysis to address this concern. Studies were identified using the PubMed, EMBASE and Web of Science databases from the database inception to the end of June 2015 as well as by examining the references of retrieved articles. Two authors independently performed the eligibility evaluation and data extraction. The summary risk estimates and 95% confidence intervals (CIs) were summarized by the random-effects models. One cohort and nine case-control studies were included in the dose-response analyses. Risk of endometrial cancer increased by 6% for 100 mg/day increment in the dietary consumption of cholesterol (Odds ratio (OR) = 1.06; 95% CI = 1.00–1.12), with significant heterogeneity (I² = 64.2, P = 0.003). When stratified by study design, the result was significant in case-control studies (OR = 1.07; 95% CI = 1.01–1.13). Additionally, although the direction of the associations were consistent in the subgroup analyses stratified by study characteristics and adjustment for potential confounders, not all of them showed statistical significance. In summary, findings of the present dose-response meta-analysis partly support the positive association between dietary cholesterol consumption and risk of endometrial cancer. Since only one cohort study was included, more prospective studies and pooled analysis of observational studies are warranted to confirm our findings in the future.

• cholesterol
• endometrial cancer
• epidemiology
• meta-analysis

• Birth control
• Cancer
• Contraception
• Malignancy

• Breast Neoplasms/prevention & control
• Colonic Neoplasms/prevention & control
• Contraceptive Agents/administration & dosage
• Female
• Genital Neoplasms, Female/prevention & control
• Humans
• Neoplasms/prevention & control

• acetaminophen
• endometrial cancer
• meta-analysis
• observational study
• systematic review

• Acetaminophen/therapeutic use
• Case-Control Studies
• Databases, Factual
• Endometrial Neoplasms/epidemiology
• Female
• Humans
• Observational Studies as Topic
• Prospective Studies

The purpose of this study is to determine the associations between statin use and breast cancer survival and risk by performing a systematic review and meta-analysis. We searched PubMed, Embase and Web of Science up to August 2015 for identifying relevant prospective or case-control studies, or randomized clinical trials. Five prospective studies involving 60,911 patients reported the association between statin use and breast cancer mortality. Eleven prospective studies, 12 case-control studies and 9 randomized clinical trials involving 83,919 patients reported the association between statin use and breast cancer risk. After pooling estimates from all available studies, there was a significantly negative association between pre-diagnosis statin use and breast cancer mortality (for overall survival (OS): hazard ratio (HR) = 0.68, 95% confidence interval (CI) 0.54–0.84; for disease specific survival (DSS): HR = 0.72, 95% CI 0.53–0.99). There was also a significant inverse association between post-diagnosis statin use and breast cancer DSS (HR = 0.65, 95% CI 0.43–0.98), although the association with breast cancer OS did not reach statistical significance (HR = 0.71, 95% CI 0.48–1.07). Additionally, there was a non-linear relationship for the duration of post-diagnosis statin use with breast cancer specific mortality. On the other hand, with regards to the relationship between statin use and breast cancer risk, no significant association was detected. Our analyses suggest that although statin use may not influence breast cancer risk, the use of statin may be associated with decrease mortality of breast cancer patients. Further large-scale studies are warranted to validate our findings.

• breast cancer
• meta-analysis
• mortality
• risk
• statin

• Epidemiology
• meta-analysis
• parity
• risk
• thyroid cancer

• Breastfeeding
• Epidemiological studies
• Meta-analysis
• Risk
• Thyroid cancer

In the past decades, a large number of randomized controlled trials (RCTs) on the efficacy of ligustrazine injection combined with conventional antianginal drugs for angina pectoris have been reported. However, these RCTs have not been evaluated in accordance with PRISMA systematic review standards. The aim of this study was to evaluate the efficacy of ligustrazine injection as adjunctive therapy for angina pectoris.

The databases PubMed, Medline, Cochrane Library, Embase, Sino-Med, Wanfang Databases, Chinese Scientific Journal Database, Google Scholar, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, and the Chinese Science Citation Database were searched for published RCTs. Meta-analysis was performed on the primary outcome measures, including the improvements of electrocardiography (ECG) and the reductions in angina symptoms. Sensitivity and subgroup analysis based on the M score (the refined Jadad scores) were also used to evaluate the effect of quality, sample size, and publication year of the included RCTs on the overall effect of ligustrazine injection.

Eleven RCTs involving 870 patients with angina pectoris were selected in this study. Compared with conventional antianginal drugs alone, ligustrazine injection combined with antianginal drugs significantly increased the efficacy in symptom improvement (odds ratio [OR], 3.59; 95% confidence interval [CI]: 2.39 to 5.40) and in ECG improvement (OR, 3.42; 95% CI: 2.33 to 5.01). Sensitivity and subgroup analysis also confirmed that ligustrazine injection had better effect in the treatment of angina pectoris as adjunctive therapy.

The 11 eligible RCTs indicated that ligustrazine injection as adjunctive therapy was more effective than antianginal drugs alone. However, due to the low quality of included RCTs, more rigorously designed RCTs were still needed to verify the effects of ligustrazine injection as adjunctive therapy for angina pectoris.

Epidemiological studies have provided controversial evidence of the association between dietary fat intake and endometrial cancer (EC) risk. To address this inconsistency, we conducted this dose-response meta-analysis by total dietary fat intake, based on epidemiological studies published up to the end of June 2015 identified from PubMed, EMBASE and Web of Science. Two authors (RH and Q-JW) independently performed the eligibility evaluation and data extraction. All differences were resolved by discussion with the third investigator (LJ). Random-effects models were used to estimate summary relative risks (RRs) and 95% confidence intervals (CIs). Overall, the search yielded 16 studies (6 cohort and 10 case-control studies) that involved a total of 7556 EC cases and 563,781 non-cases. The summary RR for EC for each 30g/day increment intake was 0.98 (95%CI = 0.95–1.001; I² = 0%; n = 11) for total dietary fat. Non-significant results were observed in plant-based fat (summary RR = 1.05, 95%CI = 0.94–1.18; I² = 0%; n = 5) and animal-based fat (summary RR = 1.17, 95%CI = 0.92–1.36; I² = 85.0%; n = 6). Additionally, the null associations were observed in almost all the subgroup and sensitivity analyses. In conclusion, findings of the present meta-analysis suggested a lack of association between total dietary fat intake and EC risk. Further studies, especially prospective designed studies are warranted to confirm our findings.

The association between parity and endometrial cancer risk is inconsistent from observational studies. We aimed to quantitatively assess the relationship by summarizing all relevant epidemiological studies. PubMed (MEDLINE), Embase and Scopus were searched up to February 2015 for eligible case–control studies and prospective studies. Random-effects model was used to pool risk estimations. Ten prospective studies, 35 case-control studies and 1 pooled analysis of 10 cohort and 14 case-control studies including 69681 patients were identified. Pooled analysis revealed that there was a significant inverse association between parity and risk of endometrial cancer (relative risk (RR) for parous versus nulliparous: 0.69, 95% confidence interval (CI) 0.65–0.74; I² = 76.9%). By evaluating the number of parity, we identified that parity number of 1, 2 or 3 versus nulliparous demonstrated significant negative association (RR = 0.73, 95% CI 0.64–0.84, I² = 88.3%; RR = 0.62, 95% CI 0.53–0.74, I² = 92.1%; and RR = 0.68, 95% CI 0.65–0.70, I² = 20.0% respectively). The dose-response analysis suggested a nonlinear relationship between the number of parity and endometrial cancer risk. The RR decreased when the number of parity increased. This meta-analysis suggests that parity may be associated with a decreased risk of endometrial cancer. Further studies are warranted to replicate our findings.